Fenofibrate protects endothelial cells against the harmful effects of TNF-alpha by Westcott, Corli et al.
22
Fenofi brate protects endothelial 
cells against the harmful effects 
of TNF-alpha
FENOFIBRATE AND 
ENDOTHELIAL 
PROTECTION
*Division of Medical Physiology, Faculty of Medicine and Health 
Sciences, University of Stellenbosch, Cape Town, South Africa
# Biotechnology, Research and Innovation Platform, Medical Research 
Council, Tygerberg, South Africa.
 
Address for correspondence: 
Dr Corli Westcott
Division of Medical Physiology
Faculty of Medicine and Health Sciences
University of Stellenbosch
PO Box 24
Cape Town
8000
South Africa
Email: 
corli2@sun.ac.za
Corli Westcott*, Amanda Genis*, Mashudu Mthethwa*, 
Roxanne Graham*, Derick van Vuuren*, Barbara Huisamen*,# 
and Hans Strijdom*
ABSTRACT
INTRODUCTION
Fenofibrate, a fibric acid-derivative and peroxisome proliferator-
activated receptor-alpha (PPARα) agonist, is best known for its 
high density lipoprotein cholesterol increasing and triglyceride 
reducing effects.(1,2) In addition to its anti-dyslipidaemic actions, 
fenofibrate has been shown to exert several pleiotropic (non-
lipid) vasculo-protective effects, including antioxidant,(3-6) anti-
thrombotic,(7,8) and anti-apoptotic effects.(9,10) 
Many of the beneficial pleiotropic effects of fenofibrate on the 
vasculature are thought to be driven by increased endothelium-
dependent nitric oxide (NO) release, as demonstrated in a 
study which showed that fenofibrate treatment improved 
hyperaemia-induced flow-mediated dilatation in patients with 
hypertriglyceridaemia.(1) NO is an important endothelium-
derived molecule involved in the maintenance of vascular 
homeostasis,(11) and is synthesised by the NO synthase (NOS) 
enzyme family, viz. endothelial NOS (eNOS), neuronal NOS 
(nNOS) and inducible NOS (iNOS).(12) In addition to its NO 
modulatory effects, fenofibrate has been shown to possess anti-
oxidant properties. For example, fenofibrate reduced super-
oxide levels and apoptosis in human umbilical vein endothelial 
cells (HUVECs) exposed to high glucose treatment,(10) and 
increased superoxide dismutase activity in rat brain micro-
vessels.(3)
Cardiovascular risk factors, such as diabetes mellitus and obesity, 
as well as atherosclerosis are associated with inflammation and 
increased levels of pro-inflammatory cytokines.(13-15) Endothelial 
cells are important cellular targets of pro-inflammatory cytokines 
such as tumour necrosis factor alpha (TNF-alpha),(16) and 
exposure of the endothelium to TNF-alpha can result in 
endothelial dysfunction.(13) In fact, TNF-alpha is considered one 
of the main promoters of endothelial dysfunction during the 
early stages of atherosclerosis.(17) Hence, investigations into 
potential therapeutic interventions that can prevent TNF-alpha 
Introduction: Fenofi brate exerts pleiotropic effects on 
endothelial cells (ECs) by, amongst others, increasing 
nitric oxide (NO) production. We aimed to investigate 
fenofi brate’s putative benefi cial actions in healthy or 
TNF-alpha-induced dysfunctional ECs. 
Methods: Fenofi brate-induced pro-vasodilatory re-
sponses were assessed in aortic rings (50 - 125μM; 
30min) with and without L-NMMA (100μM). Rat cardiac 
microvascular ECs were treated with fenofi brate (30 
and 50μM; 1h). In the pre-treatment experiments, feno-
fi brate (50μM) was administered one hour before TNF-
alpha treatment (20ng/ml; 24h). NO-production (DAF- 
2/DA or Griess assay), mitochondrial ROS-production 
(MitoSox™), cell viability (propidium iodide staining), 
and changes in the expression/phosphorylation of 
critical endothelial proteins were measured by Western 
blotting. 
Results: Fenofi brate increased NO-production ˜2-fold in 
healthy ECs (p<0.05 vs. vehicle).  A ˜ 23% pro-vasodilatory 
response was induced in aortic rings, which was reversed 
by L-NMMA (p<0.05 vs. fenofi brate). Fenofi brate pre-
treatment ameliorated TNF-alpha-induced endothelial 
dysfunction by reversing the loss of NO, improving 
oxidative stress, restoring cell viability and preventing 
caspase-3 activation. Protective effects were under-
pinned by ˜47% and ˜49% up-regulation of activated 
eNOS and AMP-kinase, respectively (p<0.05 vs. TNF-
alpha). 
Conclusions: Fenofi brate protects TNF-alpha-induced 
dysfunctional ECs via up-regulated eNOS-NO, reduced 
oxidative stress and improved cell viability. These novel 
fi ndings warrant further investigations to explore the 
potential use of fenofi brate as an anti-endothelial dys-
function therapeutic agent.  SAHeart 2017;14:22-34
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induced vascular damage are important. Endothelial dysfunction 
is characterised by reduced NO bioavailability and impaired 
endothelium-dependent vasodilation(18) and is regarded as an 
early, reversible precursor and predictor of atherosclerosis.(19-20) 
Although the exact cellular mechanisms underlying TNF-alpha 
induced endothelial dysfunction are still under scrutiny,(22) 
oxidative stress is generally recognised as the candidate 
common mechanism.(23-24) 
In view of the fact that endothelial dysfunction is potentially 
reversible, early therapeutic interventions could prevent 
future cardiovascular disease. Previous studies have investi-
gated the effect of fenofibrate on TNF-alpha induced changes 
in the vasculature. Zhao and Wu (2004) showed that feno-
fibrate reduced TNF-alpha levels in the serum of rabbits on a 
high cholesterol diet as well as TNF-alpha secretion from 
adipocytes.(26) Furthermore, fenofibrate pre-treatment prior 
to TNF-alpha administration in HUVECs was able to inhibit 
TNF-alpha induced expression of cluster of differentiation 40 
(CD40).(27-28) Huang, et al. (2009) showed that fenofibrate 
prevented increases in monocyte adhesion to endothelial cells 
in TNF-alpha-stimulated human aortic endothelial cells.(29) 
However, as far as we are aware, no previous studies have 
investigated whether fenofibrate can protect vascular endo-
thelial cells against the harmful effects of TNF-alpha with regards 
to NO production, ROS generation and cell viability. Therefore, 
the present study aimed to investigate whether pre-treatment 
with fenofibrate protects adult rat endothelial cells against TNF-
alpha induced endothelial dysfunction, and if so, whether the 
protection is associated with the modulation of NO biosynthesis, 
ROS generation and markers of cell death.
MATERIALS AND METHODS
Research materials and reagents 
Endothelial growth medium (Endothelial cell basal medium-2; 
EBM-2) was purchased from Clonetics (Cambrex Bio Science, 
Walkersville, USA); 4.5-Diaminofluorescein diacetate (DAF-2/
DA) and NG-Monomethyl-L-arginine monoacetate (L-NMMA) 
were from Calbiochem (San Diego, California, USA). Attach-
ment factor, trypsin (500 BAEE units trypsin /180μg EDTA•4Na 
per ml in Dulbecco’s PBS), dihydroethidium (DHE) and 
MitoSoxTM Red were from Life Technologies (Carlsbad, 
California, USA). Fenofibrate, human recombinant TNF-alpha, 
dihydrorhodamine-123 (DHR-123), dimethoxy-1, 4-naphtho-
quinone (DMNQ), diethylamine NONOate (DEA/NO), 
dimethyl sulfoxide (DMSO), acetylcholine, phenylephrine and 
Griess Reagent were from Sigma-Aldrich (St Louis, Missouri, 
USA). The following antibodies were from Cell Signaling 
Technologies (Beverly, Massachusetts, USA): eNOS, phos-
phorylated-eNOS (Ser 1177); Akt, phosphorylated Akt (Ser 
473); AMP activated protein kinase (AMPK), phosphorylated 
AMPK (Thr 172); cleaved caspase-3 and IκBα. p22PHOX, and 
nitrotyrosine antibodies were purchased from Santa Cruz 
Biotechnologies. Propidium iodide (PI) solution and cell staining 
buffer were purchased from Bio-Legend (Biocom-Biotech, San 
Diego, California, USA). Enhanced chemiluminescence (ECL) 
detection reagent, ECL hyperfilm, and Horseradish peroxidase-
linked anti-rabbit IgG were from AEC Amersham (Bucking-
hamshire, UK). Polyvinylidene difluoride (PVDF) membrane 
(Immobilon™-P) and authentic peroxynitrite were from 
Millipore (Bedford, MA, USA). Foetal bovine serum was 
purchased from Highveld Biological (Lyndhurst, South Africa). 
All other chemicals and buffer reagents were purchased from 
Merck (Damstadt, Germany).
Adult rat aortic ring studies
Animal care
Experiments were conducted according to the “Guide for 
the care and use of laboratory animals” published by the US 
National Institutes of Health (NIH publication no. 85 - 23, 
revised 1985) and the South African Bureau of Standards 
(SANS 10386, 2008). Ethics approval was received from the 
University of Stellenbosch (Project number: SU-ACUM11 - 
00002). Male Wistar rats weighing 200 - 250g were supplied 
by the Central Research Facility of the Faculty of Medicine 
and Health Sciences of Stellenbosch University where they 
were housed in temperature controlled conditions (22 - 24oC). 
Animals were subjected to a 12 hour light and dark cycle and 
had free access to standard rat chow and water. Animals were 
anaesthetised with pentobarbital (160mg/kg) until deep anaes-
thesia was reached as evidenced by the lack of a pedal reflex. 
They were then euthanised by exsanguination before excision 
of the aortas.   
Assessment of aortic vasoactive responses
The chest cavity was opened by incision and thoracic aorta 
excised and placed in ice cold Krebs-Henseleit solution, 
containing sodium chloride (NaCl) 119mM, sodium bicarbonate 
(NaHCO3) 25mM, potassium chloride (KCl) 4.75mM, mono-
potassium phosphate (KH2PO4) 1.2mM, magnesium sulfate 
heptahydrate (MgSO4.7H2O) 0.6mM, sodium sulfate (Na2SO4) 
0.6mM, calcium chloride monohydrate (CaCl2.H2O) 1.25 mM, 
and glucose 10mM. Excess perivascular fat and connective 
tissue were removed. Aortas were cut into 3 - 4mm ring 
segments that were subsequently mounted onto 2 steel hooks 
in a 25ml organ bath (AD Instruments, Bella Vista, New South 
Wales, Australia) containing oxygenated (95% O2 and 5% CO2) 
Krebs-Henseleit buffer at 37oC. Aortic ring tension was 
recorded with an isometric force transducer (TRI202PAD, 
Panlab, lCornellà, Barcelona, Spain) and data analysed with 
LabChart 7 sofware (Dunedin, New Zealand). The isometric 
tension measurement protocol was based on a modification of 
a previously described technique.(29) Briefly, mounted aortic 
rings were stabilised under a resting tension of 1.5g during 
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which time the Krebs-Henseleit buffer in the organ bath was 
changed every 10 minutes for 30 minutes with pre-warmed 
Krebs-Henseleit solution. Following this, all aortic rings were 
pre-contracted with phenylephrine administration (1μM) to 
the organ bath until the maximum contraction tension was 
reached. Subsequently, aortic rings were randomly divided into 
groups that either received cumulative concentrations of the 
known pro-vasodilatory agent, acetylcholine (30nM - 10μM), or 
cumulative concentrations of fenofibrate (50μM - 125μM). 
Pharmacological NOS inhibition was achieved by adding 
L-NMMA (100μM) to the water bath 15 minutes before the 
phenylephrine-fenofibrate protocol. 
Endothelial cell studies
Cell cultures
Primary adult rat cardiac microvascular endothelial cells 
(CMECs) and aortic endothelial cells (AECs) were purchased 
from VEC Technologies (Rensselaer, New York, USA). CMECs 
and AECs were maintained in EBM-2, supplemented with 10% 
feotal bovine serum, growth factors and antibiotics as per 
the supplier’s instructions. CMEC and AEC subcultures were 
passaged to a maximum of 4 generations in 35mm attachment 
factor-coated petri dishes. All cultures received fresh growth 
medium every second day. Endothelial cell culture purity was 
regularly monitored by light microscopic validation of the typical 
monolayer, cobblestone appearance exhibited by cultured 
endothelial cells(30,31) as well as confirmation by flow cytometric 
analysis of >80% positive staining with the endothelial cell-
specific marker, acetylated low density lipoprotein labeled 
with 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindo-carbocyanine per-
chlorate (Dil-ac-LDL; Biomedical Technologies, Stoughton, 
Massachusetts, USA).(30,31) All cell cultures were grown until 
100% confluency was reached for experimental purposes.
Experimental conditions and procedures
Cultured CMECs (fully confluent) were washed once with 
phosphate buffered saline (PBS) prior to treatment with 
fenofibrate or vehicle solution. Fenofibrate was dissolved in 
0.2% DMSO. Cells were treated with 30 or 50μM fenofibrate 
or 0.2% DMSO for 1 hour. Untreated, time-matched control 
samples received fresh medium only. In a separate set of 
investigations, the putative protective effects of fenofibrate 
pretreatment were explored in TNF-alpha-treated CMECs. 
Briefly, CMECs were washed once with PBS, pretreated with 
fenofibrate (50μM) for 1 hour, after which TNF-alpha (20ng/
ml) was administered to the fenofibrate-pretreated cells for an 
additional 24 hours without changing the growth medium. 
Separate CMEC samples were treated with fenofibrate for 25 
hours or TNF-alpha for 24 hours respectively. Control samples 
were incubated with growth medium, and vehicle control 
samples with 0.2% DMSO (vehicle) in a time-matched fashion. 
After treatment, cells were washed twice with PBS and pre-
pared for flow cytometric, Griess or Western blot analyses. 
Flow cytometric analyses 
Intracellular levels of NO, superoxide and peroxynitrite were 
determined by flow cytometric analysis of the mean fluores-
cence intensity generated with the fluorescent probes: DAF-2/
DA (10 μM; sensitive for NO), DHE (5μM; sensitive for 
superoxide), DHR-123 (2μM; sensitive for peroxynitrite), and 
MitoSoxTM (5μM; sensitive for mitochondrial ROS). The flow 
cytometry-based assays used in this study were previously 
extensively characterised and validated.(32,33) Briefly, after the 
respective treatment periods as described above, cultured cells 
were washed twice with PBS and incubated at 37°C for an 
additional 2 hours with DAF-2/DA, DHE or DHR-123, or 15 
minutes with MitoSoxTM to allow the fluorescent probes to 
react with their respective intracellular target molecules. 
Following this, the fluorescent probe-containing cells were 
washed once with PBS and removed from culture by 
trypsinization. Trypsinized cells were centrifuged for 3 minutes 
at 1 000rpm and the pellet subsequently re-suspended in 
PBS in preparation for flow cytometric analysis. To verify the 
sensitivity of the fluorescent probes for their target mole-
cules, positive control experimental groups were included in 
which cells were treated with 100μM of the NO-donor, DEA/
NO (for DAF-2/DA sensitivity), 10μM of the superoxide 
donor, DMNQ (DHE sensitivity), or 100μM authentic peroxy-
nitrite (for DHR-123 sensitivity) respectively, as previously 
described.(32-34) All flow cytometric analyses were performed 
with a Becton Dickinson FACSCalibur® (Becton, Dickinson and 
Co, San Jose, California, USA) using WinMDI® version 2.9 
software (Purdue University Cytometry Laboratories, West 
Lafayette, USA). Acquisition was set at 10 000 events/sample, 
and the mean fluorescence intensity of DAF-2/DA and DHE 
was analysed in flow channel 1 and flow channel 2 respectively. 
DHR-123 and MitoSoxTM were analysed in flow channel 3. 
Loss of cell viability was measured by means of flow cytometric 
analysis of propidium iodide staining according to the manu-
facturer’s instructions. Trypsinized cells were incubated with 
propidium iodide for 15 minutes in the dark before flow 
cytometric analysis. Samples were analysed in flow channel 2 
and 5 000 events were acquired per sample. Data analysis was 
performed with WinMDI® version 2.9 software. 
Plate reader analyses with the Griess Reagent
In order to validate the results obtained with the DAF-2/DA 
assay, a different NO detection method, the Griess assay, was 
employed to measure the cellular release of nitrites (breakdown 
products of NO). CMECs and AECs were cultured in 24-well 
microplates until confluent. Cells were treated with 50μM 
fenofibrate in 500μl PBS for 1 hour, after which an equal volume 
of 500μL Griess reagent(35) was added to each well. After 15 
minutes incubation, the colorimetric reaction was measured 
at 540nM on a FLUOstar Omega platereader from BMG 
Labtech (Ortenberg, Germany). Serial dilutions of a nitrite 
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FIGURE 1: Aortic ring relaxation induced by the 
administration of cumulative concentrations of 
fenofi brate.
Fenofibrate administered cumulatively (1:0μM; 2:50μM; 3:100μM 
and 4:125μM) induced a vasodilatory response in phenylephrine 
pre-contracted aortic rings, which was attenuated by pre-
incubation with the non-selective NOS inhibitor L-NMMA 
(100μM). Acetylcholine administration (cumulative concentra-
tions: 1:0μM; 2:0.03μM; 3:1μM and 4:10μM) served as a positive 
control of maximum endothelium-dependent pro-vasodilatory 
response, and DMSO (cumulative concentrations: 1:0%; 2:0.02%; 
3:0.04% and 4:0.05%) was the vehicle control. n=4/group. 
* = p<0.05 vs. acetylcholine,  # = p<0.05 vs. L-NMMA + Fenofibrate,  
◊ = p<0.05 vs. DMSO.
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standard (NaNO2 dissolved in PBS; 0 - 10μM) were included 
in each microplate to create a standard curve. Data were 
calculated from the standard curve and expressed as 
μM nitrites.
Western Blot analyses
CMECs were lysed using a lysis buffer (20.0mM Tris-HCl; 
1.0mM EGTA; 1.0mM EDTA; 150mM NaCl; 1.0mM 
β-glycerophosphate; 2.5mM sodium pyrophosphate; 0.1% 
sodiumdodecylsulphate; 1.0mM sodium orthovanadate; 1.0% 
Triton-X100; 10μg/ml leupeptin; 10μg/ml aprotinin; 50nM 
sodium fluoride; 50μg/ml phenylmethylsulfonyl fluoride) and 
homogenised with 0.5mm zirconium beads and a Bullet 
BlenderTM (Next Advance, Inc., New York, USA). Protein 
content was determined with the Bradford assay.(36) Equal 
amounts of protein (20μg) were separated on SDS-poly-
acrylamide gels and electro-transferred to a polyvinylidene 
difluoride membrane. Non-specific protein binding sites on the 
membrane were blocked with 5% fat free milk powder, 
dissolved in tris buffered saline-Tween-20 (0.1%) for 1 hour. 
Membranes were incubated overnight with the following 
primary antibodies: eNOS and phosphorylated-eNOS (Ser 
1177), Akt and phosphorylated-Akt (Ser 473), AMPK and 
phosphorylated-AMPK (Thr 172), IκBα, cleaved caspase-3, 
nitrotyrosine and p22PHOX. The secondary antibody was 
horseradish peroxidase-linked anti-rabbit IgG or anti-mouse 
IgG and protein bands were visualised with the ECL™ 
chemiluminescent system. Films were densitometrically analysed 
(UN-SCAN-IT, Silk Scientific, Orem, UT, USA). Ponceau stains 
were used as loading control. The ponceau stain was 
densitometrically analysed and quantified. All data were then 
expressed as a ratio of total protein over the quantified ponceau 
value for that specific lane in the blot. The relative phos-
phorylation status of proteins was expressed as a ratio of 
phosphorylated over total protein expression. Membranes 
were stripped of primary and secondary antibodies with 0.2M 
NaOH and re-probed with a different antibody; therefore 
some proteins shared ponceau loading controls. 
Statistical analysis
All flow cytometry data were calculated as mean ± standard 
error of the mean, with values expressed as % of control 
(control adjusted to 100%). Propidium iodide data were 
expressed as % change in non-viable (stained) cells compared 
to control (control adjusted to 100%). Total sample sizes for 
the flow cytometry investigations were derived from experi-
ments repeated at least 2 - 3 times on separate days using cells 
cultured from different batches (total n-values are shown below 
each graph). For western blot data, controls were adjusted to 
1 and sample sizes were a minimum of n=3/group. Student’s 
t-tests or one-way analysis of variance (with Bonferroni multiple 
comparison test or Dunnet post hoc test) were used to 
determine statistical significance. All aortic ring isometric tension 
data were expressed as the % relaxation of maximum con-
traction and statistically analysed by means of two-way analysis 
of variance followed by Bonferonni post-test. Differences with 
a p value <0.05 were considered statistically significant. Data 
were analysed using GraphPad Prism 5 software (GraphPad 
Software, San Diego, California, USA). Sample sizes are 
indicated below each graph.
RESULTS
Cumulative NOS-dependent relaxation of 
aortic rings
Cumulative administration of fenofibrate induced a maximum 
vasodilatory response of 23% in phenylephrine pre-contracted 
aortic rings after 30 minutes (vs. DMSO vehicle: 10% relaxation; 
p<0.05) (Figure 1). Pretreatment with the NOS inhibitor, 
L-NMMA (100μM), significantly attenuated the fenofibrate-
induced relaxation from 23% - 8% (p<0.05 vs. fenofibrate), 
thereby confirming NOS-dependence. 
26
FENOFIBRATE AND ENDOTHELIAL PROTECTION
Fenofi brate treatment increases intracellular 
NO and nitrite concentration, and decreases 
ROS levels, with no effect on cell viability
The NO-donor, DEA/NO significantly increased DAF-2/DA 
fluorescence, confirming the NO-sensitivity of the probe 
(Figure 2a). At 1 hour, both 30μM and 50μM fenofibrate 
increased DAF-2/DA fluorescence by 1.7-fold and 2.2-fold 
respectively vs. control (p<0.05) (Figure 2a). The superoxide-
donor, DMNQ, significantly increased DHE fluorescence 
compared to control; however, fenofibrate exerted no effects 
on DHE fluorescence at either 30μM or 50μM treatment 
(Figure 2b). Authentic peroxynitrite significantly increased 
DHR-123 fluorescence compared to control. Fenofibrate 
treatment resulted in decreased DHR-123-fluorescence com-
FIGURE 2: Fenofi brate treatment (1 hour) in healthy CMECs.
A. Intracellular NO production increased in both 30μM and 50μM fenofibrate treatment groups as measured by DAF-2/DA fluorescence. The 
NO-donor, DEA / NO (100μm) was used as positive control. Data expressed as % of control (control adjusted to 100%); n=4 - 9/group. 
B. Intracellular superoxide production remained unchanged compared to control as measured by DHE fluorescence. The superoxide donor, 
DMNQ (10μM) was used as positive control. Data expressed as % of control (control adjusted to 100%); n=6 - 14/ group.  
C. Intracellular peroxynitrite production decreased in both 30μM and 50μM fenofibrate treatment groups as measured by DHR-123 fluorescence. 
Authentic peroxynitrite (100μM) was used as positive control. Data expressed as % of control (control adjusted to 100%); n=7 - 8/group. 
D. Cell viability as measured by propidium iodide staining was not affected by fenofibrate. Brief exposure (5 minutes) of the cells to osmotic stress 
by incubation with distilled water served as positive control. Data expressed as % change in propidium iodide staining cells from control (control 
adjusted to 100%); n=8 - 15/group. 
* = p<0.05 vs. control, ◊ = p<0.05 vs. DMSO, # = p<0.05 vs. fenofibrate 30μM, @ = p<0.05 vs. fenofibrate 50μM.
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pared to control at both 30μM (36% decrease; p<0.05) and 
50μM (42% decrease; p<0.05) (Figure 2c). Cell viability in 
CMECs were not affected by 1 hour fenofibrate (30 and 50μM) 
treatment (Figure 2d). DEA/NO increased the concentration 
of nitrites by 2-fold compared to control (p<0.0001) in CMECs 
(Figure 3a); similarly, 1 hour treatment with 50μM fenofibrate 
increased the concentration of nitrites by 2-fold compared to 
control (p<0.001) (Figure 3b), and by 60% in AECs (p<0.05) 
(Figure 3c).
Fenofi brate pre-treatment prevents TNF-alpha 
induced effects on NO and ROS synthesis, and 
prevents loss of cell viability
DAF-2/DA fluorescence measurements indicated that TNF-
alpha treatment (20ng/ml; 24 hours) resulted in a 17% reduction 
in NO-production (p<0.05 vs. control) (Figure 4a), which was 
associated with a 2.9-fold increase in the fluorescence intensity 
of the mitochondrial ROS probe, MitoSoxTM (p<0.05 vs. 
control) (Figure 4b). Furthermore, there was a 39% increase 
in the non-viable (propidium iodide-staining) cells in the 
TNF-alpha treatment group compared to control (p<0.05) 
(Figure 4c). Taken together, the aforementioned findings are 
highly suggestive of the induction of endothelial dysfunction in 
the TNF-alpha treated CMECs. 
Fenofibrate pre-treatment (50μM) prevented the TNF-alpha-
induced reduction in NO-production; in fact, NO measure-
ments increased by 40% compared to TNF-alpha only treat-
ment (p<0.05) (Figure 4a). In addition, there was a marked 
2.5-fold reduction in mitochondrial ROS levels in the feno-
fibrate pre-treatment group compared to TNF-alpha only treat-
ment (p<0.05) (Figure 4b). Finally, fenofibrate pre-treatment 
prevented the loss of cell viability observed in the TNF-alpha 
only treatment group (p<0.05) (Figure 4c). 
Fenofi brate pre-treatment increases eNOS 
(Ser 1177) and AMPK phosphorylation and 
prevents TNF-alpha-induced expression of 
p22PHOX and IκBα
TNF-alpha treatment was associated with a ~45% reduction in 
eNOS expression compared to control, which was not affected 
by fenofibrate pre-treatment (Figures 5a, b). However, activated 
eNOS (phospho eNOS Ser 1177) levels increased by ~47% in 
the fenofibrate pre-treatment group compared to TNF-alpha 
treatment alone, and a ~41% increase was observed in the 
phosphorylated / total eNOS ratio of the fenofibrate pre-
treatment group compared to control (Figures 5a, c, d). 
Although total AMPK expression was not altered in any of the 
groups, activated AMPK (phospho AMPK Thr 172) levels 
increased by ~49% in the fenofibrate pre-treatment group 
compared to TNF-alpha treatment alone (Figures 5a, f). Akt 
expression, activation and phosphorylated/total Akt ratio were 
not affected by any of the treatment protocols (Figures 5a, h). 
Nitrotyrosine levels were not altered in any of the groups 
compared to control (Supplementary Figure S1). Fenofibrate 
pre-treatment reduced the expression of the NADPH-oxidase 
subunit p22PHOX by ~50% compared to TNF-alpha treat-
FIGURE 3: Concentration nitrites as measured by the 
Griess assay in CMECs and AECs.
A.  DEA/NO (positive control) increased nitrite concentration in 
the supernatant; n=7 - 8 per group.
B.  Concentration nitrites released into supernatant increased 
after 1 hour treatment with 50μM fenofibrate in CMECs; 
n=8 - 13/group. 
C.  Concentration nitrites released into supernatant increased 
after 1 hour treatment with 50μM fenofibrate in AECs; 
n=8 - 11/group. 
* = p<0.05 vs. control.
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FIGURE 4: Effects of pre-treatment with fenofi brate (50μM) administered one hour prior to TNF-alpha treatment 
(20ng/ml; 24 hours) on NO production, mitochondrial ROS generation and cell viability in CMECs.
A.  Intracellular NO production increased in the fenofibrate treatment group and decreased in TNF-alpha treatment group compared to control. 
Fenofibrate pre-treatment increased intracellular NO production compared to TNF-alpha treatment only. NO production was measured by 
DAF - 2/DA fluorescence and data expressed as % of control (control adjusted to 100%); n=4 - 11/group.
B.  Mitochondrial ROS production increased in the TNF-alpha treatment group compared to control, and the increase was prevented by 
fenofibrate pre-treatment. Mitochondrial ROS production was measured by MitoSoxTM Red fluorescence and data expressed as % of control 
(control adjusted to 100%); n=3 - 4/group.
C.  TNF-alpha treatment increased the % non-viable cells compared to control and the increase was prevented by fenofibrate pre-treatment. Data 
expressed as % change in propidium iodide staining cells from control (control adjusted to 100%).
D. TNF-alpha treatment increased the levels of cleaved caspase-3 compared to control, and fenofibrate pre-treatment prevented the increase.
E.  Representative Western blot of cleaved caspase-3;  n=8 -15/group. 
* = p<0.05 vs. control, @ = p<0.05 vs. TNF-α, # = p<0.05 vs. DMSO, ◊ = p<0.05 vs. fenofibrate. Feno = Fenofibrate, Feno+TNF-α = Fenofibrate pre-treatment.
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p-eNOS Ser 1177
-- 130 kDaTotal-eNOS
Ponceau
p-AMPK Thr 172
-- 62 kDaTotal-AMPK
Ponceau
p-Akt
-- 60 kDaTotal-Akt
Ponceau
FIGURE 5.1: Effects of pre-treatment with fenofi brate (50μM) administered one hour prior to TNF-alpha treatment 
(20ng/ml; 24 hours) on the expression and phosphorylation of eNOS, AMPK and Akt in CMECs.
A.  Representative western blots of phosphorylated eNOS (ser 1177), total eNOS, phosphorylated AMPK (Thr 172), total AMPK, phosphorylated 
Akt (Ser 473), and total Akt.
B. Total eNOS expression decreased in TNF-alpha only and fenofibrate pre-treatment groups compared to control.
C. Phosphorylated eNOS levels increased in fenofibrate pre-treatment vs. TNF-alpha only group.
D. Phosphorylated/total eNOS ratio increased in fenofibrate pre-treatment vs. control.
* = p<0.05 vs. Control. @ = p<0.05 vs. TNF-alpha. n = 3/group. Feno = fenofibrate, Fenofibrate + TNF-α = fenofibrate pretreatment.
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ment alone (Figures 6a, b). TNF-alpha treatment resulted in 
the activation of the NF-KB pathway as demonstrated by a 
decrease of ~36% in the expression of IκBα; however, 
fenofibrate pre-treatment failed to prevent the reduction in 
IκBα (Figures 6a, c). TNF-alpha treatment increased the 
expression of cleaved caspase-3 levels by ~2.6-fold compared 
to control, further signifying the induction of endothelial 
dysfunction, whilst fenofibrate pre-treatment prevented the 
increase in cleaved caspase-3 levels (Figures 4d, e). 
DISCUSSION
In the present study, we demonstrated that fenofibrate protects 
endothelial cells against the harmful effects of TNF-alpha, and 
that the protection is associated with the up-regulation of 
eNOS-NO biosynthesis, reduced ROS production, and pre-
vention of cell death. 
In the baseline experiments, healthy endothelial cells responded 
to short term fenofibrate treatment by a marked increase in 
NO production. This observation was further supported by a 
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modest, but significant eNOS-dependent pro-vasodilatory 
response to fenofibrate administration in rat aortic rings. The 
ability of fenofibrate to increase NO production in endothelial 
cells has previously been demonstrated. For example, in 
cultured human umbilical vein endothelial cells (HUVECs), 
fenofibrate (30μM; 10 minutes) treatment resulted in a ~2-fold 
increase in NO production,(37) in line with the increases 
observed in our study. Similarly, a 2-fold increase in NO pro-
duction was observed in human glomerular microvascular 
endothelial cells treated with fenofibrate (100μM) for 1 hour.(9) 
In bovine aortic endothelial cells, fenofibrate (50μM) was shown 
to increase eNOS expression and activity after 48 hours 
treatment; however, the authors did not measure NO pro-
duction.(38) The general consensus in the literature that feno-
fibrate up-regulates NO biosynthesis in vascular endothelial 
cells has potentially important implications, as NO is associated 
with beneficial effects in the cardiovascular system via, among 
others, anti-inflammatory, anti-apoptotic and anti-necrotic 
mechanisms.(39) In our hands, fenofibrate treatment affected 
neither baseline superoxide production, nor intracellular levels 
of the harmful radical peroxynitrite compared to control 
conditions, demonstrating that the large increases in NO 
FIGURE 5.2: Effects of pre-treatment with fenofi brate (50μM) administered one hour prior to TNF-alpha treatment 
(20ng/ml; 24 hours) on the expression and phosphorylation of eNOS, AMPK and Akt in CMECs.
E. Total AMPK expression was not affected by any of the treatment groups.
F. Phosphorylated AMPK levels increased in the fenofibrate pre-treatment group vs. TNF-alpha treatment only.
G. Phosphorylated/total AMPK ratio was not affected by any of the treatment groups.
H. Phosphorylated/total Akt ratio was not affected by any of the treatment groups.   
* = p<0.05 vs. Control. @ = p<0.05 vs. TNF-alpha. n = 3/group.
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production were not associated with oxidative or nitrosative 
stress. Cell viability remained unaffected compared to untreated 
control conditions. 
Following the baseline studies in healthy CMECs, we investi-
gated whether the effects of fenofibrate would translate into 
protection in a model of dysfunctional endothelial cells induced 
by a harmful inflammatory stimulus, with regards to NO 
production, ROS generation and cell viability. To our know-
ledge, the endothelioprotective properties of fenofibrate have 
not previously been demonstrated in this context. Previous 
data from our laboratory showed that 24 hours treatment of 
CMECs with TNF-alpha at 20ng/ml resulted in endothelial 
dysfunction as determined by reduced NO production, eNOS 
down-regulation and increased oxidative stress.(40) The same 
concentration and treatment period were used in the present 
study, and endothelial dysfunction was demonstrated by 
reduced eNOS protein expression associated with decreased 
NO levels, increased mitochondrial ROS generation, decreased 
cell viability and increased apoptosis. Furthermore, the pro-
inflammatory effects of TNF-alpha were confirmed by increased 
NF-KB activity. In addition to our own previous findings,(40) 
others have also shown that TNF-α down-regulates eNOS 
and/or reduces NO production in various models of endothelial 
FIGURE 6: Effects of pre-treatment with fenofi brate 
(50μM) administered one hour prior to TNF-alpha 
treatment (20ng/ml; 24 hours) on the expression of 
p22PHOX, IκBα and cleaved caspase-3.
A. Representative western blots of p22PHOX and IκBα.
B.  Fenofibrate pre-treatment decreased the expression of 
p22PHOX compared to TNF-alpha only.
C.  The expression of IκBα was decreased compared to control in 
the TNF-alpha only and fenofibrate pre-treatment groups.
* = p<0.05 vs. Control. # = p<0.05 vs. DMSO. ◊ = p<0.05 vs. Fenofibrate, 
@ = p<0.05 vs. TNF-alpha. ^ = p<0.05 vs. Fenofibrate + TNF-alpha, n = 3/group. 
Feno = fenofibrate, Fenofibrate + TNF-α = fenofibrate pre-treatment.
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SUPPLEMENTARY FIGURE S1: Nitrotyrosine levels.
A.  Representative Western blot for nitrotyrosine.
B.   No changes were found in nitrotyrosine levels after DMSO, 
fenofibrate, TNF-α or fenofibrate + TNF-α treatment.
n = 3/group. 
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cells.(41-43) Furthermore, the induction of ROS generation by 
TNF-alpha,(44,45) as well as its pro-apoptotic effects(47,47) have 
extensively been described. 
We have demonstrated that fenofibrate pre-treatment pro-
tected the endothelial cells against the harmful effects of TNF-
alpha with regards to NO production, ROS generation and cell 
viability. The protection was characterised by the prevention of 
a decrease in NO production, the prevention of an increase in 
mitochondrial ROS production and p22PHOX expression, the 
prevention of a loss of cell viability, and the prevention of 
increases in cleaved caspase-3 levels. Pre-treatment of CMECs 
with fenofibrate resulted in increased activated eNOS (p-eNOS 
Ser 1177) levels compared to cells treated with TNF-alpha 
only, as well as a significantly greater p-eNOS Ser 1177 / total 
eNOS ratio compared to untreated control. The up-regulation 
of eNOS activation was associated with a ~40% increase in NO 
generation compared to TNF-alpha only. Indeed, many of the 
pleiotropic effects of fenofibrate on vascular endothelium have 
been attributed to eNOS phosphorylation and activation;(9,37,38) 
however, most studies have not investigated fenofibrate-
induced effects on the eNOS-NO biosynthesis pathway in the 
context of injured or dysfunctional endothelial cells. AMPK and 
Akt are regarded as two of the most important upstream 
regulators of eNOS activation via Ser 1177 phosphorylation.(48) 
In the present study, fenofibrate pretreatment increased 
activated AMPK (phospho AMPK Thr 172) levels compared to 
TNF-alpha only treatment, which corresponds with the 
increased activation of eNOS. In this regard, fenofibrate has 
previously been associated with increased phosphorylation of 
AMPK (Thr 172) in a variety of endothelial cell types;(9,37,49,50) 
however, none of these studies were conducted in the context 
of TNF-alpha induced injury. Tomizawa, et al. (2011) showed 
that 100μM fenofibrate activates AMPK and Akt in human 
glomerular microvascular endothelial cells with resultant activa-
tion of eNOS (Ser 1177) within 1 hour of treatment. Similarly, 
Murakami, et al. (2006) demonstrated that fenofibrate activates 
AMPK and eNOS (Ser 1177) in HUVECs. These findings were 
observed at a concentration of 30μM at 10 minutes. Kim, et al. 
(2007) showed fenofibrate protects endothelial cells against 
apoptosis via a PPARα independent, AMPK dependent activa-
tion. Although the latter study used a similar concentration of 
fenofibrate (50μM) compared to ours, it was performed in 
retinal endothelial cells and treatment lasted for 1 hour. From 
the literature, it is clear that eNOS and AMPK can be activated 
within minutes of stimulation.(37) Although we did perform 
experiments to investigate the short term effects of fenofibrate 
on eNOS and AMPK activation (5, 15 and 30 minutes), no 
evidence of activation by phosphorylation was detected 
(Supplementary, Figure S2). None of the treatment protocols in 
the present study exerted any effects on Akt expression or 
activation. It therefore seems that upstream Akt played no role 
in the phosphorylation of eNOS in our hands. The literature 
appears to be contradictory regarding fenofibrate’s effects on 
Akt; whereas some studies showed an association with 
increased phosphorylation of Akt (Thr 308) in human glomerular 
SUPPLEMENTARY FIGURE S2: Short term activation 
and phosphorylation of AMPK and eNOS.
A.   Representative Western blots for AMPK and eNOS (Ser 1177).
B.   5, 15 and 30min treatment with 50μM fenofibrate significantly 
decreased the P/T AMPK ratio compared to control samples.
C.   5, 15 and 30min treatment with 50μM fenofibrate did not 
change P/T eNOS levels.
* = p<0.05 vs. control,, n = 3/group. 
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microvascular endothelial cells(9) and Akt (Ser 473) in hepa-
tocytes,(51) others demonstrated inhibition of the Akt pathway 
in HUVECs,(52) and hepatocytes.(53) 
The induction of 2 oxidative stress markers by TNF-alpha in 
the CMECs (p22PHOX and mitochondrial ROS levels) was 
prevented by fenofibrate pretreatment. Fenofibrate’s anti-
oxidant properties have previously been demonstrated in an 
in vivo study by reducing superoxide anion levels and p22PHOX 
expression in a model of nicotine-treated rat aortic tissue;(54,55) 
however the authors did not investigate the effects in endo-
thelial cells. Although fenofibrate pretreatment did not alter 
TNF-alpha-induced activation of NF-KB in our hands, it was 
associated with a marked improvement in cell viability and 
reduced caspase-3 mediated apoptosis. NO appears to have 
paradoxical effects on apoptosis.(56) NO can inhibit caspase-3 
by s-nitrosation,(57) and it is possible that fenofibrate resulted in 
reduced caspase-3 mediated apoptosis due to increased levels 
of NO. Although anti-apoptotic effects of fenofibrate have 
previously been demonstrated in human retinal endothelial cells 
subjected to serum deprivation,(49) and in HUVECs exposed to 
high glucose,(10) we could not find any studies investigating the 
anti-apoptotic effects of fenofibrate in the context of TNF-
alpha induced endothelial injury. Repeating pre-treatment 
studies in the presence of a NOS-inhibitor would have added 
great value to the study, and the lack thereof is acknowledged 
as a shortcoming.
In conclusion, the present study provides novel data demon-
strating that fenofibrate pretreatment protects adult rat endo-
thelial cells against the harmful, pro-endothelial dysfunction 
effects of TNF-alpha with regards to NO and ROS production, 
and cell viability parameters. The findings are important in view 
of the fact that therapeutic interventions may prevent endo-
thelial dysfunction. Inflammation has emerged as a pivotal role-
player in the pathophysiology of arterial diseases (reviewed 
in 15) and therapies aimed at preventing this condition should 
be further researched. Although our data suggest that 
fenofibrate shows potential as a possible future therapeutic 
option in the preventative treatment of TNF-alpha-induced 
endothelial dysfunction, more studies are needed to further 
explore and validate these promising observations. 
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